Allarity Therapeutics Inc. Faces Class Action Lawsuit for Alleged Misrepresentation of Dovitinib

### Allarity Therapeutics Faces Class Action Lawsuit Over Alleged Misrepresentation

Allarity Therapeutics, Inc. is currently embroiled in a class action lawsuit filed by the Schall Law Firm, alleging violations of the Securities Exchange Act of 1934. This lawsuit targets investors who acquired Allarity securities between May 17, 2022, and July 19, 2024, a period during which the firm asserts that the company and its executives issued false or misleading statements concerning their drug Dovitinib and its regulatory approval process. The lawsuit claims that these misrepresentations heightened regulatory scrutiny and misled investors about the likelihood of enforcement actions related to an ongoing investigation.

The crux of the complaint revolves around assertions that Allarity downplayed the risks associated with the Dovitinib New Drug Application (NDA) and the Dovitinib-DRP Pre-Market Approval (PMA). By portraying a more favorable view of their regulatory standing, the company allegedly misled investors, leading to significant financial losses when the truth surfaced. As a result of these actions, the lawsuit seeks to hold Allarity accountable for the alleged deception and to provide a channel for affected shareholders to reclaim their losses.

Currently, the class action is not yet certified, meaning that investors who suffered losses during the specified period are encouraged to engage with the Schall Law Firm before the November 12, 2024, deadline. The firm specializes in securities class action lawsuits and offers free consultations for shareholders interested in pursuing their claims. As this legal process unfolds, it raises questions about corporate governance and the accountability of biotechnology firms in the context of regulatory compliance.

In related news, Allarity continues to focus on its drug development pipeline while navigating the complexities of regulatory approvals. The company’s ability to manage legal challenges alongside its core operations will be critical in maintaining investor confidence and advancing its therapeutic initiatives.

As the class action progresses, Allarity's leadership may need to address these allegations publicly to reassure stakeholders of their commitment to transparency and ethical business practices. The outcome of this lawsuit could have significant implications not only for the company but also for its investors and the broader biotechnology sector.